A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.-论文-万方医学网

作者： David S,Hong ^[1] ; Peter,Rosen ^[2] ; A Craig,Lockhart ^[3] ; Siqing,Fu ^[1] ; Filip,Janku ^[1] ; Razelle,Kurzrock ^[1] ; Rabia,Khan ^[1] ; Benny,Amore ^[4] ; Isaac,Caudillo ^[5] ; Hongjie,Deng ^[5] ; Yuying C,Hwang ^[5] ; Robert,Loberg ^[5] ; Gataree,Ngarmchamnanrith ^[5] ; Darrin M,Beaupre ^[5] ; Peter,Lee ^[2]

作者单位： MD Anderson Cancer Center, Houston, TX, USA. ^[1] Tower Cancer Research Foundation, Beverly Hills, CA, USA. ^[2] Washington University School of Medicine, St. Louis, MO, USA. ^[3] Amgen Inc., Seattle, WA, USA. ^[4] Amgen Inc., Thousand Oaks, CA, USA. ^[5]

主题词投药, 口服(Administration, Oral);成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);曲线下面积(Area Under Curve);剂量效应关系, 药物(Dose-Response Relationship, Drug);疲劳(Fatigue);女(雌)性(Female);人类(Humans);高血压(Hypertension);免疫组织化学(Immunohistochemistry);原位杂交, 荧光(In Situ Hybridization, Fluorescence);男(雄)性(Male);代谢清除率(Metabolic Clearance Rate);中年人(Middle Aged);恶心(Nausea);肿瘤(Neoplasms);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质c-met(Proto-Oncogene Proteins c-met);哒嗪类(Pyridazines);缓解诱导(Remission Induction);治疗结果(Treatment Outcome);三唑类(Triazoles)

DOI 10.18632/oncotarget.4472

PMID 26155941

发布时间 2024-03-24

检索历史清除

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

Oncotarget

相似文献

Oncotarget

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors.

Oncotarget

相似文献

Oncotarget

相关期刊

检索历史清除